Incidence patterns of early onset colon cancer by race and stage in the US.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18168-e18168
Author(s):  
Nishi Shah ◽  
Ana Acuna-Villaorduna ◽  
Sanjay Goel
Keyword(s):  
Colon Cancer ◽  
American Indians ◽  
Early Onset ◽  
Age Groups ◽  
Young Patients ◽  
Cancer Registries ◽  
Age Group ◽  
Annual Percent Change ◽  
Percent Change ◽  
The Us

e18168 Background: Several studies show that incidence of colorectal cancer is increasing among young individuals. However, information on incidence of early onset colon cancer by race and stage is lacking. Methods: We analyzed incidence of colon cancer using National Program of Cancer Registries database which covers 99% of the US population. We identified colon cancer using ICD-O-3 code 8000-9049, 9056-9139, 9141-9589, along with the variable for site from cecum to sigmoid colon for years 2001 to 2015. SEER*Stat was used to calculate age-adjusted rates, trends and annual percent change. Results: Age adjusted incidence rate for colon is 31.2 cases per 100,000 among the entire population. Incidence in the age group of 15-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, 80+ years is 2.4, 14.3, 39.8, 86, 165.8, 232.3 per 100,000 respectively. The distribution of colon cancer by race for age groups is listed in table. When evaluating the incidence trend in each race for early onset colon cancer, the trend shows a rise in whites for both age groups (Annual Percent Change [APC] 3.4%, 1.5% for 15-39 years, 40-49 years of age respectively, p < 0.05). The trend in blacks on the other hand shows a rise of 1.2% (p < 0.05) in 15-39 years of age and a small but statistically significant decrease in incidence in 40-49 years of 0.5% (p < 0.05). In Asian Pacific Islanders (API) and American-Indians or Alaskan Natives (AI), the trend is not significant for either age groups. In the age groups above 50 years, the trend shows a decrease in incidence of colon cancer in all races. The rise in incidence for colon cancer in 15-39 years age group appears higher in localized disease as compared to metastatic disease (6.5% vs 2.8% for localized vs distant site of disease). Conclusions: This study highlights differences in incidence of early onset colon cancer among young patients by race and stage. Although there have been more cases of early onset colon cancers in blacks, the rise in incidence is higher in whites. With colonoscopy, there has been decrease in incidence of colon cancer for patients > 50 years for all races and stages. [Table: see text]

Trends of endometrial cancer incidence from 2000 to 2015 in the United States.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 5591-5591
Author(s):  
V V Pavan Kedar Mukthinuthalapati ◽  
Muhammad Zain Farooq ◽  
Shweta Gupta
Keyword(s):  
Endometrial Cancer ◽  
Age Groups ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
P Value ◽  
Age Group ◽  
Histologic Subtype ◽  
The Us ◽  
Histologic Subtypes

5591 Background: Recent studies have shown that obesity related cancers are increasing in incidence in the US as the rates of obesity rise and some cancers, like colorectal cancer, are occurring in younger age groups. We studied trends in incidence of endometrial cancer (EC), one of the obesity related cancers, in a population wide analysis. Methods: We analyzed data from all cases of EC between 2000 and 2015 from 18 US cancer registries using the National Cancer Institute’s Surveillance, Epidemiology and End Results Program. SEER*Stat was used to query the database for annual percent changes (APC), incidence ratios and percent change in incidence across different age groups, years of diagnosis, histologic subtypes, grade and race. We also studied the reported rates and trends of obesity in the US. Results: APC of age-adjusted EC incidence between 2000 and 2015 was +0.9% (95% confidence interval (CI) 1.1-0.6, p value<0.05). Incidence of EC rose from 17.8 per 100,000 to 19.7 per 100,000 during the same duration. APC for EC incidence for age groups 20-39 and >40 were +3.2% (p-value <0.05) and +0.8% (p value <0.05), respectively. For the age-group 20-39, endometrioid EC was the only histologic subtype that rose in incidence, with an APC of +5.5% and absolute percentage change of 156%. The APC of EC in 20-39 age group was more for whites (3.5%, p-value<0.05) and Asians (2.2%, p-value<0.05) than blacks (1.8, p-value <0.05). CDC reported an increase in obesity rates in adults from 30.5% in 2000 to 37.7% in 2014. Table shows trends of EC incidence in age groups 20-39 and >40 years across various histologic subtypes. (Abbreviations: S significant, NS not significant, NC non-calculable). Conclusions: Endometrial cancer, especially of endometrioid histology, is increasing in incidence and is occurring more often in the younger population. The concomitant rise in obesity rates during the same period point towards a possible causality of the increased in incidence of EC. Population based strategies are needed to decrease the trends in obesity so as to decrease the risk of endometrial cancer in younger women. [Table: see text]

Clinicopathological characteristics and impact on efficacy of three versus six months of adjuvant chemotherapy in early-onset colon cancer: ACHIEVE and ACHIEVE-2 trials.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 60-60
Author(s):  
Eiji Oki ◽  
Masahito Kotaka ◽  
Dai Manaka ◽  
Manabu Shiozawa ◽  
Yasuhiro Sakamoto ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Early Onset ◽  
Lung Metastases ◽  
Age Groups ◽  
Disease Free Survival ◽  
Clinicopathological Characteristics ◽  
Related Data ◽  
Incidence And Mortality

60 Background: Colorectal cancer (CRC) incidence and mortality have decreased since the 1970s but several data such as the SEER CRC registry show that the incidence of early onset colon cancer (eoCC, age 20-49) and RC keep increasing. There is limited results suggesting eoCC may have different behaviors compared to traditional CC (tCC, age ≥ 50). Methods: Individual patient data of 1,805 high-risk stage II/III colon cancer (CC) patients (pts) as the modified ITT population in ACHIEVE and ACHIEVE-2 trials were investigated. Clinicopathological features and treatment-related data were assessed by age group. Disease-free survival (DFS) was assessed by Kaplan-Meier curves and Cox multivariable models adjusted by trials, regimen, T and N. Results: Of the 1,805 pts, eoCC were 155 pts (8.6%). Using 5% difference between age groups as clinically meaningful cutoff, eoCC had similar gender (female, 52 vs 48%), PS (PS = 1, 1 vs 4%), risk group (high-risk, 43 vs 42%) and T stage (T4, 30 vs 30%) as tCC, while eoCC were less likely right-sided colon primary (32 vs 39%), had N1 disease (48 vs 54%), and treated by FOLFOX (16 vs 23%). Overall, eoCC significantly had a worse DFS than tCC (3y-DFS, 75 vs 82%; Adjusted Hazard Ratio = 1.40: 95% Confidence Interval, 1.00-1.95: p= 0.0478); in addition, similar DFS were observed among tCC pts (age 50-69 vs >70). eoCC experienced less neutropenia, thrombocytopenia and stomatitis, but had more diarrhea, nausea and/or vomiting. There were 38 and 297 pts with an initial relapse in eoCC and tCC, respectively. Of those, peritoneal metastases were more frequently seen in eoCC (n = 13, 34%) than in tCC (n = 63, 21%) (p = 0.097), whereas liver and lung metastases were similar between the two groups. Impact on DFS of 3 versus 6 months of adjuvant chemotherapy in eoCC (3y-DFS, 75% vs 76%) is similar to that in tCC (83% vs 81%). Conclusions: eoCC had unique characteristics; the difference in DFS between eoCC and tCC were potentially due to a different metastatic spread. eoCC had a different adverse event profile compared to tCC. No impact on DFS of treatment duration in eoCC was suggested. Clinical trial information: UMIN000013036.

scholarly journals Factors Associated With Early-Onset Esophageal Cancer in Tanzania: A Case-Control Study

2018 ◽  
Vol 4 (Supplement 1) ◽  
pp. 29s-29s
Author(s):  
Geoffrey Buckle ◽  
Elia J. Mmbaga ◽  
Alan Paciorek ◽  
Larry Akoko ◽  
Katrina Deardorff ◽  
...  
Keyword(s):  
Risk Factors ◽  
Household Income ◽  
Early Onset ◽  
Case Control Study ◽  
Age Groups ◽  
Young Patients ◽  
Second Hand Smoke ◽  
Factors Associated ◽  
History Of ◽  
Control Study

Abstract 89 Purpose Previous studies have characterized geographic clusters of esophageal cancer (EC) in East Africa. Many of the epidemiologic features of EC in this context are shared globally with other clusters, including high rates, male predominance, and squamous cell histology. A unique feature in East Africa is the high proportion of young patients, with a recent case series reporting up to 24% of patients age < 45 years. The aim of the current study was to assess factors that are associated with early-onset EC in Tanzania (TZ). Methods We performed a secondary analysis of a previous case-control study. Patients with newly diagnosed EC were recruited at Muhimbili National Hospital and Ocean Road Cancer Institute in 2014 to 2016. Hospital controls were identified from patients with nonmalignant conditions and matched 1:1 for gender and age ± 10 years. Risk factors were assessed through interviews. Logistic regression was used to estimate age-specific odds ratios (ORs) of EC for exposures across age groups (30 to 44 years, 45 to 59 years, and ≥ 60 years) and for interactions with age. Results A total of 473 cases and 473 controls were enrolled. Median ages were 59 years (range, 30 to 91 years) for cases and 55 years (range, 31 to 88 years) for controls. Among cases, 102 patients (22%) were age 30 to 44 years, 144 patients (30%) were age 45 to 59 years, and 227 patients (48%) were age ≥ 60 years. High household income was protective for those age 30 to 44 years (OR, 0.08; 95% CI, 0.01 to 0.69) and 45 to 59 years (OR, 0.13; 95% CI, 0.04 to 0.45), but not for those age ≥ 60 years (effect modification P = .047). Family history of EC was associated with a higher risk of EC among those age 45 to 59 years (OR, 3.8; 95% CI, 1.02 to 14.47) and age ≥ 60 years (OR, 6.63; 95% CI, 1.50 to 29.37), with no effect among those age 30 to 44 years (effect modification P = .019). Second-hand smoke and infrequent teeth cleaning were also associated with early-onset EC, but did not differ significantly across age groups. Additional factors associated with EC risk across all ages were firewood use (cooking), kerosene use (lighting), work on a maize farm, and in-home grain and nut storage. Protective factors were the regular use of medication, surrogates of high socioeconomic status (TV, radio, refrigerator, indoor toilet, and electricity), and charcoal or gas cooking. Conclusion Multiple exposures were identified as risk factors for early-onset EC in TZ. In age-stratified analyses, household income, second-hand smoke, and poor dental hygiene emerged as possible risk factors, whereas family history of EC had strong associations among the older but not the young age group. Our results suggest that environmental factors may underlie the high incidence of young patients with EC in TZ. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST No COIs from the authors.

Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3364-3364
Author(s):  
Mohamad Mohty ◽  
Myriam Labopin ◽  
Gerard Socié ◽  
Noel-Jean Milpied ◽  
Michel Attal ◽  
...  
Keyword(s):  
Disease Control ◽  
Conflicts Of Interest ◽  
Age Groups ◽  
Young Patients ◽  
Working Party ◽  
Dose Intensity ◽  
Risk Groups ◽  
Age Group ◽  
Sibling Donor ◽  
Related Risk

Abstract Abstract 3364 Poster Board III-252 RIC allo-SCT is an attractive treatment modality for AML patients not eligible for standard MAC regimens. While comorbidities may represent an obstacle to the use of a MAC regimen irrespective of age, most centres usually use an age threshold around 50 years for the use of a RIC regimen. Since RIC regimen proved to significantly decrease early non-relapse mortality (NRM) after allo-SCT, investigators are currently tempted by the use of RIC regimens in lower age groups with the aim to decrease NRM and optimize allogeneic immunotherapy. The aim of this analysis was to compare outcomes (leukemia-free survival: LFS, NRM, and relapse incidence) between patients receiving the classical Bu-Cy MAC regimen vs. patients receiving a Flu-Bu RIC regimen prior to allo-SCT. Since the use of RIC in young patients is still limited, the analysis was restricted to patients aged >40 years, who were transplanted using an HLA identical sibling donor for AML in CR1. Between 2000 and 2008, 452 patients with AML in CR1 were treated with standard MAC Bu-Cy and 376 received a Flu-Bu RIC regimen, and reported to the EBMT Registry. Patients received either allogeneic PBSC or BM from HLA-identical sibling donors. As expected, patients receiving the RIC regimen were older (median: 56 y. vs. 47 y.; p<0.0001), but the median time from CR1 to allo-SCT was shorter (99 days vs. 111 d.; p<0.0001) in the MAC group. Both groups were comparable in terms of period (median year: 2005) of allo-SCT, and donor-recipient gender distribution. In terms of AML-related risk factors, WBC, cytogenetics risk groups (good: 4.1%; intermediate: 84.1%; and poor: 11.7%), and the FAB subtype (M1-M2: 50.1%; M3: 1.2%; M4-M5: 36.1%; M0-M6-M7: 12.6%) at diagnosis, were also comparable between both groups. With a median follow-up of 13 (range, 1-100) months, the 3 years probabilities of LFS were 54±3% and 49±3% in the MAC and RIC groups respectively (p=0.32). The absence of difference in LFS is explained by a lower relapse incidence in the MAC group (25+/-3% vs. 39±3%; p<0.0001), but a higher rate of NRM (28±3 vs. 20±3%; p=0.004). However, when comparing the outcome of patients aged from 40 to 50 y. (n=351; 43%) and those aged >=50 y., the picture was different. In the 40-50 age group, LFS was 55±3% vs. 37±8%, p=0.049; relapse: 26±3 vs. 53±8%, p<0.0001; NRM: 25±3 vs. 21±9%, p=0.29, in the MAC and RIC groups respectively. On the other hand, in the >=50 y. age group, LFS was 52±5 vs. 51±3%, p=0.75; relapse: 23±5 vs. 36±3%, p=0.014; NRM: 33±4 vs. 20±3%, p=0.001, in the MAC and RIC groups respectively. In summary, in this specific setting of AML in CR1, LFS is not statistically different when using MAC or RIC allo-SCT for patients older than 50 years. However, for younger patients (40-50 y. age group), the use of RIC is associated with a higher relapse rate. Prospective trials addressing the use of RIC in patients younger than 50 years are needed. Indeed, reducing toxicity without compromising disease control could be of significant benefit to many patients, but MAC (or “more intensive” RIC regimens as being tested prospectively at present), despite the hazard of increased toxicity, may be necessary in others. Thus, the trade-off between dose intensity, toxicity, and disease control will remain to be assessed for each individual patient. Disclosures: No relevant conflicts of interest to declare.

The Difference in the Incidence and the Trend of Malignant Lymphomas in Japan and the United States.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2695-2695
Author(s):  
Dai Chihara ◽  
Hidemi Ito ◽  
Tomohiro Matsuda ◽  
Akiko Shibata ◽  
Tomotaka Sobue ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Hematologic Malignancies ◽  
The United States ◽  
Cumulative Exposure ◽  
Malignant Lymphomas ◽  
Annual Percent Change ◽  
Percent Change ◽  
Nodular Sclerosis ◽  
The Us ◽  
The Difference

Abstract Abstract 2695 Background: Malignant lymphomas (ML) are heterogeneous groups that the detailed classification is evolving dramatically. An incidence of malignant disease in certain population reflects cumulative exposure to environment, genetics and their combination overtime. Therefore, a comparison of incidences in various population and their secular trends is very helpful to understand etiology of disease. The aim of this study is to assess the incidence and the trend of each ML subtypes and to evaluate the difference between Japan and US. Materials and Methods: We used the data from a population-based cancer registry in Japan and from the Surveillance Epidemiology and End Results (SEER) program 9. Registry data of the US, SEER 9 included 95,155 cases and the data of Japan included 48,658 cases. The period covered in this analyses was 1993 to 2006 in Japan and 1993 to 2008 in the US. Rates of sex-specific, age-standardized incidence with 95% confidence intervals were estimated and standardized by age-adjustment according to the world standard population. We also estimated the annual percent change using joinpoint regression analysis and evaluated the significance of the trend. Results: The overall age-standardized incidence rate of all malignant lymphomas per 100,000 in 2006 was 22.4 for males and 16.0 for females in the US, 7.4 for males and 4.9 for females in Japan. The incidence is higher in the US than Japan with most of the subtypes especially for the nodular sclerosis HL, CLL/SLL and FL. In general, B-cell lymphomas showed large difference in incidence while T-cell lymphomas (TCL) showed similar incidence between Japan and the US. The total numbers of ML are constantly increasing in Japan but not in the US as shown in the figure {annual percent change (95%CI), Japan; +2.6% (2.1, 3.1), US; +0.2% (−0.0, 0.4)}. As for details, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma and the total numbers of TCL are constantly increasing in both countries. Conclusion: In conclusion, we showed the marked difference in the incidence and the trend of hematologic malignancies between Japan and the US. The incidence of hematologic malignancies is lower in Japan than the US, but is increasing significantly. The most remarkable difference in the incidence was seen with nodular sclerosis HL, CLL/SLL and FL which was consistent with previous reports. Even with the TCL, the incidence seems to be similar to higher in the US except for the ATLL. The improvement in the quality of cancer registry systems and the organization of these registries between countries enables us to unite the data worldwide that will bring us new insights. Solid line and circle are the data of the US. Dashed line and hollow circle are the data of Japan. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region

2021 ◽  
Author(s):  
Brittny C Davis Lynn ◽  
Pavel Chernyavskiy ◽  
Gretchen L Gierach ◽  
Philip S Rosenberg
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Estrogen Receptor ◽  
African American Women ◽  
Breast Cancer Incidence ◽  
Age Groups ◽  
The United States ◽  
Age Group ◽  
Annual Percent Change ◽  
Hispanic White

Abstract Background Incidence of estrogen receptor (ER)-negative breast cancer, an aggressive subtype, is highest in United States (US) African American women and in southern residents but has decreased overall since 1992. We assessed whether ER-negative breast cancer is decreasing in all age groups and cancer registries among non-Hispanic White (NHW), non-Hispanic Black (NHB), and Hispanic White (HW) women. Methods We analyzed 17 Surveillance, Epidemiology, and End-Results Program registries (twelve for 1992-2016; five for 2000-2016) to assess NHW, NHB, and HW trends by ER status and age group (30-39, 40-49, 50-69, 70-84 years). We used hierarchical age-period-cohort models that account for sparse data, which improve estimates to quantify between-registry heterogeneity in mean incidence rates and age-adjusted trends versus SEER overall. Results Overall, ER-negative incidence was highest in NHB, then NHW and HW women, and decreased from 1992-2016 in each age group and racial/ethnic group. The greatest decrease was for HW women ages 40-49 years with an annual percent change of –3.5%/year (95% credible interval = −4.4%, −2.7%), averaged over registries. The trend heterogeneity was statistically significant in every race/ethnic and age group. Furthermore, the incidence relative risks by race/ethnicity compared to the race-specific SEER average were also statistically significantly heterogeneous across the majority of registries and age groups (62 of 68 strata). The greatest heterogeneity was seen in HW women, followed by NHB women, and the least in NHW women. Conclusion Decreasing ER-negative breast cancer incidence differs meaningfully by US region and age among NHB and HW women. Analytical studies including minority women from higher and lower incidence areas may provide insights into breast cancer racial disparities.

Colorectal cancer under the age of 50 years in U.S. Department of Veterans Affairs: Is there a role of early screening?

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4072-4072
Author(s):  
Abdul Moiz Khan ◽  
Zainub Ajmal ◽  
Usman Naseer ◽  
Darren Gemoets ◽  
Syed Arzoo Mehdi
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
African Americans ◽  
Age Groups ◽  
Stage Iii ◽  
Age Group ◽  
Early Screening ◽  
Screening Guidelines ◽  
Colon And Rectal Cancer

4072 Background: While the overall incidence of colorectal cancer (CRC) is decreasing, the rate has increased in population under 50, with higher stages at diagnosis and a greater proportion of African Americans (AA). Hence, there is an ongoing debate about the age of CRC screening. These trends have not been studied in the VA population. Methods: ICD-10 codes C18-C20 were used to identify the cases of colon and rectal cancer in National VA Cancer Cube Registry. 43,544 cases of colon cancer, 1,278 below and 42,254 above age 50, and 19,815 cases of rectal cancer, 862 below and 18,948 above age 50 were identified between 2003-17. Younger age group was defined as patients less than 50 years old. IRB approval was obtained. Results: Our data comprised > 97% of male patients. In younger group, in the 5 year periods, 2003-07, 2008-12 and 2013-17, colon cancer rate increased from 2.59% to 2.79% to 3.59%, while for rectal cancer it increased from 3.5% to 4.3% to 5.3% (p < .0001). Blacks comprise 31.6% cases of colon cancer and 27.15% cases of rectal cancer in under 50 group, compared to 18.5% and 15.9% of cases in above 50 group respectively (p < .0001). For under 50 group, 48.6% cases of colon and 42.2% cases of rectal cancer were diagnosed in stage III or IV compared to 35.7% and 34.05% cases in above 50 group respectively (p < .0001). For colon cancer, 51.87% of patients in the younger group have a < 5 year survival, worse compared to 45.05% in 50-60 group (p < .0001) and similar to 49.3% in 60-70 group (p = .08). For rectal cancer, 5 year survival showed no difference between these groups. Stage specific survival shows no difference for either colon or rectal cancer across < 50, 50-60 and 60-70 age groups. Conclusions: Rate of CRC is rising in < 50 age group with more advanced stage at diagnosis and higher proportion of African Americans. For colon cancer, < 50 group has a worse 5 year survival as compared to 50-60 age group likely due to increased proportion of patients in stage III or IV, as there is no difference in stage specific survival. For rectal cancer, the 5 year survival or stage specific survival shows no difference in < 50, 50-60 and 60-70 groups. These results add to our understanding of the trends of CRC and should be accounted for in the screening guidelines.

Abstract 16403: Prevalence and Sex Differences in Early-onset Atrial Fibrillation - A Nation-wide Primary Care Study in Norway

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Silje M Kalstø ◽  
Ståle Nygård ◽  
Arnljot Tveit ◽  
Inger Ariansen ◽  
Ingrid E Christophersen
Keyword(s):  
Atrial Fibrillation ◽  
Primary Care ◽  
Sex Differences ◽  
Early Onset ◽  
Age Groups ◽  
Age Group ◽  
Lone Atrial Fibrillation ◽  
Primary Care Population ◽  
Primary Care Sector

Background: Several studies have reported a male:female ratio of 4:1 in lone atrial fibrillation (AF) populations. However, there have been few reports on the young population with AF, and no reports from a primary care setting. Here, we describe prevalence and sex-differences in early-onset AF in a nation-wide register-based study in the primary care sector in Norway. Methods: In Norway, with a population of 5.4 million, healthcare is publicly financed and all general practitioner (GP) claims have been recorded in the Norwegian Control and Payment of Health Reimbursement (KUHR) registry, since 2006. We identified all individuals aged ≥18 and <50 years registered with ≥1 AF diagnosis code (International Classification of Primary Care (ICPC) K78), from 2006-2019 in the KUHR registry. Based on population estimates from Statistics Norway, we calculated the prevalence of early-onset AF in 2019, as a total, by sex, and by age groups: 18-29, 30-39, 40-49. Results: We identified 5563 individuals (28.5% women, age 18-49 years) aged 18-49 in 2019 with AF diagnosed <age 50 years. In 2019, the prevalence of early-onset AF registered in all individuals up to age 50 was 0.24% (women: 0.14% (1585/1114821), men 0.34% (3978/1176555), p=1.4x10 -205 ) with a ratio of 2.5 men:women. In individuals aged 18-29 the prevalence was 0.05% (women 0.04% (164/410367), men 0.07% (292/435001), p=79x10 -8 ). For the age group 30-39 years the prevalence was 0.19% (women 0.12% (408/349639), men 0.27% (985/367730), p=3.9x10 -49 ). For the age group 40-49 years the prevalence was 0.51% (women 0.29% (1013/354815), men 0.72% (2701/373824), p=1.39x10 -155 ). Conclusion: We show that the prevalence of early-onset AF in a nation-wide primary care population is 0.24% and that the sex-difference in prevalence is smaller than previously reported in early-onset and lone AF studies. Our findings underline the need of increased awareness of AF as a disease in the young, and particularly to women in the youngest age-groups.

Prevalence-adjusted trends in U.S. healthcare spending on colorectal cancer, 1996-2016.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18819-e18819
Author(s):  
Igor Stukalin ◽  
Newaz Shubidito Ahmed ◽  
Adam Michael Fundytus ◽  
Siddharth Singh ◽  
Christopher Ma
Keyword(s):  
Colorectal Cancer ◽  
Inpatient Care ◽  
Temporal Trends ◽  
Age Groups ◽  
Healthcare Spending ◽  
Annual Percent Change ◽  
The Us ◽  
Intensity Of Care ◽  
Per Capita ◽  
Global Burden Of Diseases

e18819 Background: Colorectal cancer is rising in prevalence and associated with high healthcare costs. We estimated trends in the US healthcare spending in patients with colorectal cancer between 1996 and 2016. Methods: We used data on national healthcare spending developed by the Institute for Health Metrics and Evaluations for the Disease Expenditure Project. Corresponding US age-specific prevalence of colon cancer was estimated from the Global Burden of Diseases Study. Prevalence-adjusted, temporal trends in the US healthcare spending in patients with colorectal cancer, stratified by age groups ( < 20, 20-44, 45-64, >65) and by type of care (ambulatory, inpatient, emergency department, pharmaceutical prescriptions, nursing care and government administration) were estimated using joinpoint regression, expressed as annual percent change (APC) with 95% confidence intervals. Results: Overall, annual US healthcare spending on colorectal cancer increased from $8.85 billion (95% CI $8.17 billion, $9.53 billion) in 1996 to $10.5 billion (95% CI $9.35 billion, $11.7 billion) in 2016, with total costs increasing by 0.9%/year (95% CI 0.1%, 1.6%). After adjusting for colorectal cancer prevalence, the absolute per capita spending decreased from $8848 to $8427 and there has been no significant change over time (APC 0.3%, 95% CI, -0.2%, 0.8%). However, spending in patients > 65 decreased significantly by 1.3%/year (95% CI -2.2%, -0.5%). Inpatient care was the largest contributor to total colorectal cancer-related expenditures: in 2016, 65.9% (95% CI 59.5%, 71.0%) and 19.7% (95% CI 14.8%, 25.8%) of the total cost were spent on inpatient care and ambulatory care, respectively. Between 1996-2016, increases in the price and intensity of care (defined by the cost per encounter) was the largest positive driver of changing healthcare spending, accounting for $5.02 billion ($2.60, $7.33 billion). Conclusions: After adjusting for rising prevalence, US healthcare spending on colorectal cancer has not changed significantly since 1996, while the per capita cost continues to decrease, primarily in patients > 65 years old. Inpatient care accounts for the majority of colorectal cancer-related expenditures.

Non-Hodgkin Lymphoma and American Indians/Alaska Natives: A SEER Population Study from 2000 to 2012

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2110-2110
Author(s):  
Gustavo Figueiredo Marcondes Westin ◽  
Ronald S. Go
Keyword(s):  
American Indians ◽  
Conflicts Of Interest ◽  
Large Cell ◽  
Population Based ◽  
Alaska Natives ◽  
Lymphocytic Leukemia ◽  
Annual Percent Change ◽  
Non Hodgkin Lymphoma ◽  
Level Data ◽  
The Us

Abstract Background: American Indians and Alaska Natives (AI/AN) currently represent approximately 2% of the US population. However, population-based cancer studies are generally limited. Utilizing the Surveillance, Epidemiology and End Results Program (SEER), we investigated the incidence, major subtype distribution, and survival of non-Hodgkin lymphomas (NHL) in the AI/NA population. Methods: We queried the SEER 2000-2012 database for AI/AN patients with NHL using ICD-O-3 codes 9590-9823. We calculated their incidence rate (case/1,000,000) and trend as well as risk ratios compared to other races, age-adjusted to the US 2000 standard population. Patient level data were extracted to perform summary statistics and calculate overall survival (OS) using STATA/IC 12.1. Results: We identified 1,135 AI/NA patients with NHL. The average age was 59.6 years (range, 20-85) and 53% were males. The distribution of the major NHL subtypes resembles that seen among the rest of the population and is as follows: diffuse large B-cell (DLBCL; 28%), marginal zone (MZL; 19%), follicular (FL; 13%), small lymphocytic/chronic lymphocytic leukemia (SLL/CLL; 10%), NHL not-otherwise specified (NOS, 4%), mantle cell (MCL; 2%), anaplastic large cell (ALCL; 2%), lymphoplasmacytic (LPL; 1%), and peripheral T-cell (PTCL; 1%). The overall incidence of NHL is 26.4 and did not significantly change over the 12-year study period (Annual Percent Change 0.0, 95% CI [-0.3, 0.3]). Compared to other races, AI/NA have lower incidence of NHL including most of the major subtypes (Table). The median OS for all types of NHL combined is 4.16 years. AI/AN OS is statistically inferior compared to Whites(Figure). Conclusions: The NHLincidence in AI/NA is lowest among the major race groups and has remained stable in the past 12 years. However their OS is inferior when compared to Whites. The distribution of major NHL subtypes and OS are similar to the rest of the population. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document